Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
Fixed-duration therapy achieved deeper remissions, with undetectable MRD in 73.3% of patients treated with venetoclax-obinutuzumab and 47.2% of those treated with venetoclax-ibrutinib. For patients ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a ...
Studies show that sphingosine kinase 2 (SPHK2) is overexpressed in venetoclax-resistant cancer cells and that SPHK2 inhibition may reduce T-cell-induced activation and proliferation of ...
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic ...
Hosted on MSN
AbbVie’s venetoclax study completion: Implications for CLL treatment and market dynamics
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ‘Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients.’ ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Shazia K. Nakhoda, MD, discusses “exciting” data from the CLL-17 trial that showed ...
Fixed-duration regimens of venetoclax combined with obinutuzumab (VO) or ibrutinib (VI) show efficacy similar to that of continuous ibrutinib monotherapy in the first-line treatment of chronic ...
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...
Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results